Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

- Roche progresses R1626 into phase IIb study, called POLI 1 -

BOSTON, Nov. 2 /PRNewswire/ -- R1626, one of Roche's new investigational drugs for chronic hepatitis C virus (HCV) infection, has shown promising antiviral activity when given in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) (ribavirin), according to results being presented at the American Association for the Study of the Liver Disease (AASLD) meeting, being held in Boston, Nov. 2-6. After four weeks of treatment with this triple combination, the virus could no longer be detected in up to 81 percent of patients, with a mean decrease in viral load of 5.2 log10 from baseline. This is indicative of a robust virological response, and R1626 is being progressed into Phase IIb study as a result of these findings.

R1626 belongs to a class of antivirals called polymerase inhibitors, which are being investigated in combination with the current standard of care, pegylated interferon and ribavirin. The hope is that this combination will increase the number of patients who are able to be successfully treated for hepatitis C.

"The results from this Phase IIa study show that R1626 has a profound antiviral effect when used in combination with PEGASYS plus COPEGUS," said Dr. Paul Pockros, Scripps Clinic, San Diego, California, the lead investigator of the study. "This effect of R1626 in combination therapy, along with the lack of resistance observed to date, means that R1626 could be an exciting drug for patients with hepatitis C, if a safe and acceptable dosing regimen can be determined in future studies."

Antiviral Activity and Safety Results Being Presented at AASLD

The multicenter Phase IIa study enrolled patients with genotype 1 chronic HCV who have not previously received treatment. The objectives were to evaluate the four-week activity and safety of combining R1626 with PEGASYS alone or R1626 with PEGASYS plus COPEGUS in comparison to PEGASYS/COPEGUS,
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)...  SynCardia Systems, Inc. has received FDA approval to ... the effective use of its 50cc SynCardia temporary Total ... The FDA approval will allow SynCardia to launch ... patients. Patients enrolled in this study will receive the ... a donor heart transplant. (Caution-In the United States, ...
(Date:3/31/2015)... 2015 PGI has announced an expansion of ... America at its San Luis ... plant expansion is centered on solving the challenge of ... for personal care product manufacturers. The ... slitting and packaging, will allow customers to take advantage ...
(Date:3/31/2015)... 31, 2015  InMed Pharmaceuticals Inc. ("InMed") (CSE: ... that specializes in developing safer, more effective cannabis-based ... C. Anderson , Ph.D., to its Scientific Advisory ... who brings significant drug discovery and development expertise ... synthetic organic chemist by training with more than ...
Breaking Medicine Technology:FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4PGI Expands Manufacturing Capabilities At Mexico Plant 2InMed Pharmaceuticals Strengthens Scientific Advisory Board 2InMed Pharmaceuticals Strengthens Scientific Advisory Board 3InMed Pharmaceuticals Strengthens Scientific Advisory Board 4
... -- Tibet Pharmaceuticals, Inc. (NASDAQ: TBET ... the development, manufacturing and marketing of traditional Tibetan ...  "In recent days, we noticed that a website ... were untrue and incorrect announcements. Our company is in ...
... N.J. Feb. 27, 2012 Savient Pharmaceuticals, Inc. (NASDAQ: ... the three months ended December 31, 2011, which reflect ... KRYSTEXXA®(pegloticase). Savient ended the quarter with approximately $170 million ... million for the quarter. For the fourth quarter of ...
Cached Medicine Technology:Tibet Pharmaceuticals, Inc. Announces Intent to Go Private 2Tibet Pharmaceuticals, Inc. Announces Intent to Go Private 3Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results 2Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results 3Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results 4Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results 5Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results 6Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results 7
(Date:3/31/2015)... National (PRWEB) April 01, 2015 Every ... the S.A.D. (standard American diet) contains things banned in ... illness sky rockets every year. AlignLife Chiropractic & Natural ... patients but also their communities they can reduce the ... Throughout the year each AlignLife clinic offers workshops at ...
(Date:3/31/2015)... 31, 2015 Cosmetic Town, one of ... is proudly enduring adding news to its site while ... consumers of plastic surgery and cosmetic medicine better use ... and interconnected sections, the Cosmetic Town community is tingling ... the Cosmetic Town site navigation, News and Blog section, ...
(Date:3/31/2015)... In honor of National Disability Month, ... buying from a NMEDA QAP certified dealer. , ... nonprofit organization that provides consumer guidance and ensures ... of mobility equipment. The organization’s Quality Assurance Program ... adhere to the highest quality safety and customer ...
(Date:3/31/2015)... 2015 Many people, including the ones ... climbing, and cycling are only for able-bodied participants. ... Rehabilitation Institute aims to change that thinking. , ... host an Adaptive Sports Expo on Saturday, April 11 ... South in Hollywood. , The event will showcase ...
(Date:3/31/2015)... Malaysia (PRWEB) March 31, 2015 Students, ... and requirement for education in a drastically different way ... in which learning and training content is being delivered ... being impacted by technology in an unprecedented way with ... said Wemel Cumavoo, co-founder and CEO, My Mobile University ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town is Now Transforming so Consumer can Better Navigate 2Health News:Advanced Driving Systems Celebrates National Disability Month 2Health News:Memorial Healthcare System's Adaptive Sports Expo Encourages Physically Challenged To Go Beyond Perceived Limitations 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 3
... ELMWOOD PARK, N.J., July 2 PhytoCeuticals, Inc., ... care,formulations, who is the Fast to invent Stable ... granting IS Clinical from,Innovative Skin Care the right ... Inc. effective July 1, 2008., The IS ...
... and Eliza Hall Institute (WEHI) has contributed significantly ... biotechnology company, Bionomics, (ASX:BNO) and Germany-based pharmaceutical company, ... Licensing Agreement, Merck Serono will seek to develop ... autoimmune conditions. These prospective treatments will be based ...
... July 2 SuperGen, Inc.,(Nasdaq: SUPG ), ... and commercialization of therapies for solid tumors and,hematological ... and Chief Executive Officer, is scheduled to present ... 9, 2008 at the,Mandarin Oriental Hotel in New ...
... 2 The Female Health Company,(Amex: FHC ) ... Russell,Microcap(R) Index after the Russell Investment Group reconstituted its,comprehensive ... 27, 2008., The Russell Microcap(R) Index measures the ... the U.S. equity market. The Russell,Microcap(R) Index includes the ...
... Calif. and YOKOHAMA CITY, Japan, July 2 ... technology company,and Tokyo Electron Device Limited (TED), ... of inrevium evaluation board solutions, and,provider of ... the,distribution of Samplify,s patented Prism(TM) signal compression ...
... improved version of AmWay's MagnaBloc. , ... Memphis, TN ... pain management, is now available in a new, stronger form: ... released in the United States, and will be available worldwide within ...
Cached Medicine News:Health News:Termination of IS Clinical From Distributing PhytoCeuticals Formulas 2Health News:MS drug development agreement based on WEHI's medicinal chemistry 2Health News:SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008 2Health News:The Female Health Company Added to Russell Microcap(R) Index 2Health News:The Female Health Company Added to Russell Microcap(R) Index 3Health News:The Female Health Company Added to Russell Microcap(R) Index 4Health News:Samplify Systems Announces Distribution Agreement With Tokyo Electron Device Limited, Broadening Availability of Signal Compression Technology 2Health News:New MagnaBloc™ Product Available from Gradient Medical 2
... Projector Chart w/ Remote/Controller. Includes ... Adults & Children. Multiple 20/20 slides. ... Programmable feature allows you to customize your ... Halogen Illumination with Long Life. Variety of ...
... The Ultimate in ... Octopus 4.3 stabilizer features ... unmatched stability in the ... 4.3 Stabilizer features the ...
... Inc., the leader in beating heart bypass, ... new Starfish NS device is the first ... patient acceptance of surgical revascularization.,The Starfish NS ... the Multi-Vessel Small Thoracotomy (MVST) procedure without ...
Part of the Octopus System which includes both the Starfish & Octopus3. The Octopus3 Tissue Stabilizer is the pioneering and market-leading suction device....
Medicine Products: